The primary aim of our study is to understand the effects of Covid-19 disease on vascularinflammation and coagulation cascade, and secondarily, to investigate its utility inpredicting disease prognosis by analyzing serum PAI-1 levels in patients with differentseverity. The study is planned as a prospective, cross-sectional study that will includepatients admitted to Covid-19 services between January 18, 2021, and August 30, 2021. Atotal of 80 volunteers will be enrolled in the trial whose age, gender, and BMI areplanned to be matched.The study will be conducted on four groups. Group 1 (n=20; withmild symptoms), Group 2 (n=20; with moderate symptoms), Group 3 (n=20; with severesymptoms) and Group 4 (n=20; Control group).All participants who accepted the study will have their sociodemographic data, medicalhistory, and vital signs (respiratory rate, saturation, temperature, and blood pressurevalues) recorded at the start of the study. The pulmonologist in the study will alsoclassify the patient group's chest X-ray and chest tomography findings and the thymusgland dimensions. After all four groups of patients have given their consent for thestudy, a sample of 5cc blood will be obtained once for the PAI-1 analysis.

This randomized controlled trial will evaluate the implementation and(cost-)effectiveness of the culturally and contextually adapted Doing What Matters intimes of stress (DWM) and Problem Management Plus (PM+) stepped-care programs amongstasylum seekers, refugees, and/or migrants living in Italy. Outcomes include mentalhealth, resilience, wellbeing, health inequalities, and costs to health systems.

The aim in this study is to evaluate pain, fatigue and quality of life in patients withCovid-19 pneumonia in long-term follow-up and to investigate their relationship withpneumonia severity, age, presence of comorbidity and depression level.

The aim of this study is to investigate the effectiveness of virtual reality exercises onpain, cardiopulmonary capacity, mood and quality of life in patients with post-COVIDsyndrome.

The main objectives of ECCO-2 are: 1) Efficacy: to study whether EQUINACEA ARKOPHARMA,hard caplets containing cryogenized root of the plant Echinacea purpurea, show animprovement of the clinical manifestations and disease course in ambulatory patients withcovid-19 with a respiratory presentation and not requiring hospitalization (i.e., mildcovid-19). The drug being evaluated will be added as a supplement of the standardtreatment, with its current recommended dose for treatment of the common cold. 2) Safety:to determine that the incidence of adverse events is not higher than that seen with thestandard treatment applied in each case.

The XPHI-COVID-2 randomized study aims to investigate the moral choices in a context ofscarce resources.The participants are asked to complete the questionnaire of the Oxford UtilitarianismScale and are exposed to medical triage dilemmas.Participants are randomized between a group with reading of ethical guidelines and agroup without reading of ethical guidelines, before they are asked to complete thequestionnaire and being exposed to triage dilemmas.

Little is currently known about the immediate and long-term effect of COVID-19 on lungventilation (delivery of air to the lungs) and lung perfusion (delivery of blood to thelungs). Some people who survive COVID-19 may have lung ventilation and/or perfusioninjury that persists following COVID-19 recovery. This lung injury may be related toinflammation in the lung, breathlessness, exercise limitation and reduced quality oflife. Therefore, towards the goal of understanding the effects of COVID-19 on lunghealth, the purpose of this study is to characterize and understand the clinicalrelevance of COVID-19 related lung ventilation and perfusion injury and associatedinflammatory status, ≤4 weeks and 6-months following COVID-19 recovery in an asthmaticand healthy population. To do this, an asthmatic and healthy population who have, andhave not, been previously diagnosed with COVID-19 will be studied.

Viral pandemics, such as HIV and SARS-Cov-V1, have shown that they can lead to acute and/ or delayed neurological complications. At the actual context of the pandemicCoronavirus disease 2019 (COVID-19), neurological manifestations seem to be confirmedsince in 85% of COVID-19 patients, present neurological symptoms, including anosmia,ageusia, periorbital pain, dizziness, fatigue, even moderate headache, moderate memoryand/or behavioral disorders.However, these neurological manifestations are not well studied and their radiologicalfeatures are not well described. It is therefore important to assess these potentialneurological complications in COVID-19 patients. To the investigator knowledge, there isno previous study in the literature describing spectral brain changes in COVID +patients. Thus, the goal of this work is to describe the radiological semiology using MRIand particularly Magnetic Resonance Spectroscopic (MRS) biomarkers in the evaluation ofacute and / or delayed brain damage in COVID + patients presenting a neurologicalmanifestations that are initially related to the cranial nerves damage.

North-east area of France was hit in February 2020 by the new coronavirus disease, moreseverely than other French regions. Factors affecting the evolution of the disease andits severity have been quickly identified, among them figuring different kinds of immunedeficiency. Even if nowadays HIV infection is usually well controlled by ARV drugs, thosepatients with uncontrolled viral load and/or low CD4 cell counts, remain at higher riskof severe COVID infection. In this context, the primary objective of our study is aimedat evaluating the prevalence of SARS-CoV-2 antibodies in a cohort of HIV-infectedpatients followed-up in an HIV-infection care center. Secondary objectives are:evaluating whether the antibodies are protective or not, the kinetic of these antibodies,and HIV associated factors with the presence of antibodies.

This study investigates a new diagnostic test in detecting SARS-CoV-2, the virus thatcauses the disease COVID-19. This may help to improve testing for COVID-19.